Improving treatment for patients with chronic lymphocytic leukemia

Tait D. Shanafelt

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The last two decades have been time of tremendous progress in treatment for patients with chronic lymphocytic lymphoma (CLL). Chemoimmunotherapy (CIT) combining anti-CD20 monoclonal antibodies with purine nucleoside analogs has been a substantial advance for patients with CLL and results in increased response rates, progression-free survival, and overall survival. Despite these improved outcomes, only ~45% of patients achieve a complete remission with CIT and nearly all patients eventually relapse and their remains a need to improve efficacy. Although new combinations of traditional agents may lead to incremental progress, more substantive improvements are likely to result through therapeutic targeting of novel pathways critical to CLL B-cell survival including targeting: (1) leukemia cell apoptotic resistance; (2) survival signals mediated through the B-cell receptor; and (3) nurturing interactions with the microenvironment. In this mini-review, we summarize Mayo Clinic's recent efforts to improve CIT for patients with CLL.

Original languageEnglish (US)
JournalHematology
Volume17
Issue numberSUPPL. 1
DOIs
StatePublished - Apr 2012
Externally publishedYes

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
B-Lymphocytes
Purine Nucleosides
Therapeutics
Critical Pathways
Survival
Disease-Free Survival
Cell Survival
Leukemia
Monoclonal Antibodies
Recurrence

Keywords

  • Chronic lymphocytic lymphoma (CLL)
  • Small lymphocytic lymphoma (SLL)
  • Treatment

ASJC Scopus subject areas

  • Hematology

Cite this

Improving treatment for patients with chronic lymphocytic leukemia. / Shanafelt, Tait D.

In: Hematology, Vol. 17, No. SUPPL. 1, 04.2012.

Research output: Contribution to journalArticle

Shanafelt, Tait D. / Improving treatment for patients with chronic lymphocytic leukemia. In: Hematology. 2012 ; Vol. 17, No. SUPPL. 1.
@article{b150bba2501945f28e54e066ab162dab,
title = "Improving treatment for patients with chronic lymphocytic leukemia",
abstract = "The last two decades have been time of tremendous progress in treatment for patients with chronic lymphocytic lymphoma (CLL). Chemoimmunotherapy (CIT) combining anti-CD20 monoclonal antibodies with purine nucleoside analogs has been a substantial advance for patients with CLL and results in increased response rates, progression-free survival, and overall survival. Despite these improved outcomes, only ~45{\%} of patients achieve a complete remission with CIT and nearly all patients eventually relapse and their remains a need to improve efficacy. Although new combinations of traditional agents may lead to incremental progress, more substantive improvements are likely to result through therapeutic targeting of novel pathways critical to CLL B-cell survival including targeting: (1) leukemia cell apoptotic resistance; (2) survival signals mediated through the B-cell receptor; and (3) nurturing interactions with the microenvironment. In this mini-review, we summarize Mayo Clinic's recent efforts to improve CIT for patients with CLL.",
keywords = "Chronic lymphocytic lymphoma (CLL), Small lymphocytic lymphoma (SLL), Treatment",
author = "Shanafelt, {Tait D.}",
year = "2012",
month = "4",
doi = "10.1179/102453312X13336169156410",
language = "English (US)",
volume = "17",
journal = "Hematology",
issn = "1024-5340",
publisher = "Taylor and Francis Ltd.",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Improving treatment for patients with chronic lymphocytic leukemia

AU - Shanafelt, Tait D.

PY - 2012/4

Y1 - 2012/4

N2 - The last two decades have been time of tremendous progress in treatment for patients with chronic lymphocytic lymphoma (CLL). Chemoimmunotherapy (CIT) combining anti-CD20 monoclonal antibodies with purine nucleoside analogs has been a substantial advance for patients with CLL and results in increased response rates, progression-free survival, and overall survival. Despite these improved outcomes, only ~45% of patients achieve a complete remission with CIT and nearly all patients eventually relapse and their remains a need to improve efficacy. Although new combinations of traditional agents may lead to incremental progress, more substantive improvements are likely to result through therapeutic targeting of novel pathways critical to CLL B-cell survival including targeting: (1) leukemia cell apoptotic resistance; (2) survival signals mediated through the B-cell receptor; and (3) nurturing interactions with the microenvironment. In this mini-review, we summarize Mayo Clinic's recent efforts to improve CIT for patients with CLL.

AB - The last two decades have been time of tremendous progress in treatment for patients with chronic lymphocytic lymphoma (CLL). Chemoimmunotherapy (CIT) combining anti-CD20 monoclonal antibodies with purine nucleoside analogs has been a substantial advance for patients with CLL and results in increased response rates, progression-free survival, and overall survival. Despite these improved outcomes, only ~45% of patients achieve a complete remission with CIT and nearly all patients eventually relapse and their remains a need to improve efficacy. Although new combinations of traditional agents may lead to incremental progress, more substantive improvements are likely to result through therapeutic targeting of novel pathways critical to CLL B-cell survival including targeting: (1) leukemia cell apoptotic resistance; (2) survival signals mediated through the B-cell receptor; and (3) nurturing interactions with the microenvironment. In this mini-review, we summarize Mayo Clinic's recent efforts to improve CIT for patients with CLL.

KW - Chronic lymphocytic lymphoma (CLL)

KW - Small lymphocytic lymphoma (SLL)

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84859786210&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859786210&partnerID=8YFLogxK

U2 - 10.1179/102453312X13336169156410

DO - 10.1179/102453312X13336169156410

M3 - Article

C2 - 22507801

AN - SCOPUS:84859786210

VL - 17

JO - Hematology

JF - Hematology

SN - 1024-5340

IS - SUPPL. 1

ER -